Understanding Lmod2's role in heart muscle and dilated cardiomyopathy
Deciphering the role of Lmod2 in cardiac muscle and in dilated cardiomyopathy
This project looks at how problems with the Lmod2 protein harm heart muscle in people with dilated cardiomyopathy and explores ways to restore its function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11227167 on NIH RePORTER |
What this research studies
You can think of Lmod2 as a protein that helps build the thin filaments muscle cells need to contract, and researchers are studying how changes in Lmod2 lead to weakened hearts. They use lab models, genetic analyses, and patient-derived samples to see how mutations cause loss of Lmod2 protein and change muscle activation. The team is testing methods such as steric-blocking oligonucleotides to restore LMOD2 expression and is examining altered signalling pathways that affect contraction. Findings from these steps aim to link molecular problems to heart function and point toward targeted treatments.
Who could benefit from this research
Good fit: Ideal participants would be people diagnosed with dilated cardiomyopathy, especially those with early-onset disease or known LMOD2 mutations.
Not a fit: Patients whose heart failure is caused by ischemic heart disease, structural problems unrelated to LMOD2, or other non-LMOD2 genetic causes may be unlikely to benefit from LMOD2-directed therapies.
Why it matters
Potential benefit: If successful, this work could lead to targeted therapies that restore LMOD2 protein and improve heart function in people with dilated cardiomyopathy.
How similar studies have performed: Prior lab studies show that restoring LMOD2 expression can correct defects in models, but clinical benefit in patients has not yet been demonstrated.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Gregorio, Carol C — Icahn School of Medicine at Mount Sinai
- Study coordinator: Gregorio, Carol C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.